-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Benzinga·04/30/2025 12:35:08
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $17 price target.